Molnupiravir for oral treatment of Covid-19 in outpatients



  • 1. WHO Coronavirus Dashboard (COVID-19). Geneva: World Health Organization, 2021 (https://covid19.who.int).

  • 2. Stokes EK, Zambrano LD, Anderson KN, et al. 2019 Coronavirus Disease Surveillance – United States, January 22-May 30, 2020. MMWR Morb Mortal Wkly Rep 2020; 69:759765.

  • 3. Ko JY, Danielson ML, City M, et al. 2019 Coronavirus Disease (COVID-19) Associated Hospitalization Risk Factors: COVID-19 Associated Hospitalization Monitoring Network and Behavioral Risk Factor Monitoring System. Clin Infect Dis 2021; 72 (11):e695e703.

  • 4. Kompaniyets L, Goodman AB, Relay B, et al. Body Mass Index and Risk of COVID-19 Hospitalization, ICU Admission, Invasive Mechanical Ventilation, and Death – United States, March-December 2020. MMWR Morb Mortal Wkly Rep 2021; 70:355361.

  • 5. Wagner CE, Saad-Roy CM, Morris SE, et al. Vaccine and dynamic nationalism and control of SARS-CoV-2. Science 2021; 373 (6562):eabj7364eabj7364.

  • 6. Nguyen KH, Nguyen K, Corlin L, Allen JD, Chung M. Changes in COVID-19 vaccination reception and intention to vaccinate by socio-economic characteristics and geographic area, United States, January 6 – March 29, 2021. Ann Med 2021; 53:14191428.

  • seven. Arribas JR, Bhagani S, Lobo S, et al. Randomized trial of molnupiravir or placebo in hospitalized patients with Covid-19. NEJM Evid. DOI: 10.1056 / EVIDoa2100044.

  • 8. CA injured, Wheatley AK. Neutralizing therapeutic antibodies for COVID-19. Virus 2021; 13:628628.

  • 9. Gupta A, Gonzalez-Rojas Y, Juárez E, et al. Early treatment of Covid-19 with the neutralizing antibody SARS-CoV-2 sotrovimab. N English J Med 2021; 385:19411950.

  • ten. Fischer W, Eron JJ Jr., Holman W, et al. Molnupiravir, an oral antiviral treatment for COVID-19. June 17, 2021 (https://www.medrxiv.org/content/10.1101/2021.06.17.21258639v1). preprint.

  • 11. Cohen MS, Wohl DA, Fischer WA, Smith DM, Eron JJ. Outpatient treatment of SARS-CoV-2 infection to prevent progression of COVID-19. Clin Infect Dis 2021; 73:17171721.

  • 12. Yoon JJ, Toots M, Lee s, et al. Oral broad spectrum ribonucleoside analogue inhibitor of influenza and respiratory syncytial viruses. Antimicrobial agents Chemotherapy 2018; 62 (8):e00766-18.

  • 13. Cox RM, Wolf JD, Plemper RK. The therapeutically administered ribonucleoside analogue MK-4482 / EIDD-2801 blocks the transmission of SARS-CoV-2 in ferrets. Nat Microbiol 2021; 6:1118.

  • 14. Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human respiratory epithelial cell cultures and several coronaviruses in mice. Sci Transl Med 2020; 12 (541):ebb5883ebb5883.

  • 15. Wahl A, Gralinski THE, Johnson CE, et al. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature 2021; 591:451457.

  • 16. Abdelnabi R, Foo CS, De Jonghe S, Maes P, Weynand B, Neyts J. Molnupiravir inhibits replication of emerging SARS-CoV-2 (VoC) variants of concern in a hamster infection model. J Infect Dis 2021; 224:749753.

  • 17. Agostini ML, Pruijssers AJ, JD Chapel, et al. Small molecule antiviral beta-dN4-hydroxycytidine inhibits an intact coronavirus on replay with a high genetic barrier to resistance. J Virol 2019; 93 (24):e0134819.

  • 18. Urakova N, Kuznetsova V, Crossman DK, et al. -dN4-hydroxycytidine is a potent anti-alphavirus compound which induces a high level of mutations in the viral genome. J Virol 2018; 92 (3):e01965e17.

  • 19. Grobler J, Strizki J, Murgolo N, et al. Molnupiravir maintains antiviral activity against SARS-CoV-2 variants in vitro and in early clinical studies. In: Proceedings and summaries of IDWeek 2021, September 29-October 3, 2021. Arlington, Virginia: American Society of Infectious Diseases, 2021.

  • 20. Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of SARS-CoV-2 mutagenesis induced by molnupiravir. Nat Struct Mol Biol 2021; 28:740746.

  • 21. Chief Justice Gordon, Tchesnokov EP, RF Schinazi, Götte M. Molnupiravir promotes mutagenesis of SARS-CoV-2 via the RNA template. J Biol Chem 2021; 297:100770100770.

  • 22. Malone B, EA Campbell. Molnupiravir: code for disaster. Nat Struct Mol Biol 2021; 28:706708.

  • 23. WP Painter, Holman W, Bush JA, et al. Human safety, tolerability and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrobial agents Chemotherapy 2021; 65 (5):e02428-20e02428-20.

  • 24. Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early-onset SARS-CoV-2: a phase I, open-label, dose-escalating randomized controlled study. J Antimicrobial chemotherapy 2021; 76:32863295.

  • 25. Chawla A, Cao Y, Peter J, et al. Model-based dose selection for phase 3 evaluation of molnupiravir (MOV) in the treatment of COVID-19 in adults. In: Proceedings and abstracts of the 31st annual meeting of the European Congress of Clinical Microbiology and Infectious Diseases, July 9-12, 2021. Basel, Switzerland: European Society for Clinical Microbiology and Infectious Diseases, 2021.

  • 26. COVID-19: Drug and Biologics Development for Treatment or Prevention: Guidance for Industry. Silver Spring, MD: Food and drug administration, Can 2020 (https://www.fda.gov/regulatory-information/search-fda-guidance-documents/covid-19-developing-drugs-and-biological-products-treatment-or-prevention).

  • 27. WHO COVID-19 Case Definitions. Geneva: World Health Organization, December 16, 2020 (https://apps.who.int/iris/rest/bitstreams/1322790/retrieve).

  • 28. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4:213226.

  • 29. Hwang IK, Shih WJ, By Cani JS. Group sequential designs using a family of Type I error probability expenditure functions. Stat Med 1990; 9:14391445.

  • 30. Rosenberg ES, Holtgrave RD, Dorabawila V, et al. New COVID-19 Cases and Hospitalizations in Adults, by Immunization Status – New York, May 3 – July 25, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:13061311.

  • 31. Camisole Y, Crofoot G, Moncada PA, et al. Phase 2/3 trial of molnupiravir for the treatment of Covid-19 in non-hospitalized adults. NEJM Evid. DOI: 10.1056 / EVIDoa2100043.

  • 32. Tenforde MW, Kim SS, Lindsell Chief Justice, et al. Duration of symptoms and risk factors for delayed return to usual health in ambulatory patients with COVID-19 in a multi-state health systems network – United States, March-June 2020. MMWR Morb Mortal Wkly Rep 2020; 69:993998.

  • 33. Tenforde MW, Auto WH, EA Naioti, et al. Sustained efficacy of Pfizer-BioNTech and Moderna vaccines against hospitalizations associated with COVID-19 in adults – United States, March-July 2021. MMWR Morb Mortal Wkly Rep 2021; 70:11561162.

  • 34. Bajema KL, Dahl RM, Prill MM, et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19 Associated Hospitalization – Five Veteran’s Medical Centers, United States, Feb.1-Aug.6, 2021. MMWR Morb Mortal Wkly Rep 2021; 70:12941299.

  • 35. Gottlieb RL, Nirula A, Chen P, et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA 2021; 325:632644.

  • 36. Horby PW, Mafham M, Peto L, et al. Casirivimab and imdevimab in hospitalized patients with COVID-19 (RECOVERY): a randomized, controlled, open-label platform trial. June 16, 2021 (https://www.medrxiv.org/content/10.1101/2021.06.15.21258542v1). preprint.

  • 37. Pogue JM, Lauring AS, Gandhi TN, et al. Monoclonal antibodies for the early treatment of COVID-19 in a world of evolving SARS-CoV-2 mutations and variants. Infect Dis Open Forum 2021; 8 (7):ofab268ofab268.

  • 38. Cowman K, Guo Y, Pirofski LA, et al. Post-severe acute respiratory syndrome coronavirus 2 monoclonal antibody treatment hospitalizations as a sentinel for the emergence of viral variants in New York. Infect Dis Open Forum 2021; 8 (8):ofab313ofab313.


  • Previous The Collapsed Loan: Israel's Shin Bet Tracking of Omicron Carriers
    Next New legal battle over predator assassination in the Nevada wilderness | Nevada News